Next-Generation Approaches for the Treatment of Food Allergy

  • Jennifer A. Dantzer
  • Robert A. WoodEmail author
Immunotherapy and Immunomodulators (Brian Vickery, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Immunotherapy and Immunomodulators


Purpose of Review

IgE-mediated food allergies are an increasing health concern, and current management includes food avoidance and use of emergency medications. Effective treatment of food allergy is highly desirable. Next generation approaches for the treatment of food allergy aim to improve both safety and efficacy, potentially including long-term tolerance.

Recent Findings

Oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) will likely be integrated into clinical practice as part of food allergy management in the near future. Newer approaches, such as sublingual immunotherapy (SLIT), modified proteins, lysosomal-associated membrane protein DNA (LAMP DNA) vaccines, and the use of immunomodulatory agents, are early in development and depending on results, could also become important treatment options.


This is a review of novel approaches to the treatment of food allergy that are currently under investigation, including the use of SLIT, modified proteins, probiotics, Chinese herbal supplements, biologic therapies, and DNA vaccines, as well as a summary of the current status of OIT and EPIT.


Food allergy Treatment Immunotherapy Biologic therapy Modified proteins DNA vaccine 


Compliance with Ethical Standards

Conflict of Interest

Dr. Dantzer reports grants from NIH, grants from Aimmune, and personal fees from Maryland Chapter of the American Academy of Pediatrics, outside the submitted work; Dr. Wood reports grants from NIH, from Aimmune, from Astellas, from DBV, from Sanofi, from regeneron, and other from Up To Date, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. Nutr Res. 2011;31(1):61–75.CrossRefGoogle Scholar
  2. 2.
    Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128(1):e9–17.CrossRefGoogle Scholar
  3. 3.
    Sicherer SH. Epidemiology of food allergy. J Allergy Clin Immunol. 2011;127(3):594–602.CrossRefGoogle Scholar
  4. 4.
    Prescott SL, Pawankar R, Allen KJ, Campbell DE, Sinn JK, Fiocchi A, et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organ J. 2013;6(1):21-4551-6-21.CrossRefGoogle Scholar
  5. 5.
    Savage J, Sicherer S, Wood R. The natural history of food allergy. J Allergy Clin Immunol Pract. 2016;4(2):196–203 quiz 204.CrossRefGoogle Scholar
  6. 6.
    Blom WM, Michelsen-Huisman AD, van Os-Medendorp H, van Duijn G, de Zeeuw-Brouwer ML, Versluis A, et al. Accidental food allergy reactions: products and undeclared ingredients. J Allergy Clin Immunol. 2018;142(3):865–75.CrossRefGoogle Scholar
  7. 7.
    Versluis A, Knulst AC, Kruizinga AG, Michelsen A, Houben GF, Baumert JL, et al. Frequency, severity and causes of unexpected allergic reactions to food: a systematic literature review. Clin Exp Allergy. 2015;45(2):347–67.CrossRefGoogle Scholar
  8. 8.
    Nguyen-Luu NU, Ben-Shoshan M, Alizadehfar R, Joseph L, Harada L, Allen M, et al. Inadvertent exposures in children with peanut allergy. Pediatr Allergy Immunol. 2012;23(2):133–9.CrossRefGoogle Scholar
  9. 9.
    Fleischer DM, Perry TT, Atkins D, Wood RA, Burks AW, Jones SM, et al. Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study. Pediatrics. 2012;130(1):e25–32.CrossRefGoogle Scholar
  10. 10.
    Michelsen-Huisman AD, van Os-Medendorp H, Blom WM, Versluis A, Castenmiller JJM, Noteborn HPJM, et al. Accidental allergic reactions in food allergy: causes related to products and patient’s management. Allergy. 2018; 73(12):2377-2381.Google Scholar
  11. 11.
    Kim J, Kwon J, Noh G, Lee SS. The effects of elimination diet on nutritional status in subjects with atopic dermatitis. Nutr Res Pract. 2013;7(6):488–94.CrossRefGoogle Scholar
  12. 12.
    Hobbs CB, Skinner AC, Burks AW, Vickery BP. Food allergies affect growth in children. J Allergy Clin Immunol Pract. 2015;3(1):133–4.e1.CrossRefGoogle Scholar
  13. 13.
    Cummings AJ, Knibb RC, King RM, Lucas JS. The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy. 2010;65(8):933–45.CrossRefGoogle Scholar
  14. 14.
    Flokstra-de Blok BM, Dubois AE, Vlieg-Boerstra BJ, Oude Elberink JN, Raat H, DunnGalvin A, et al. Health-related quality of life of food allergic patients: comparison with the general population and other diseases. Allergy. 2010;65(2):238–44.CrossRefGoogle Scholar
  15. 15.
    Wood RA. Oral immunotherapy for food allergy. J Investig Allergol Clin Immunol. 2017;27(3):151–9.CrossRefGoogle Scholar
  16. 16.
    Burks AW, Sampson HA, Plaut M, Lack G, Akdis CA. Treatment for food allergy. J Allergy Clin Immunol. 2018;141(1):1–9.CrossRefGoogle Scholar
  17. 17.
    Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2008;122(6):1154–60.CrossRefGoogle Scholar
  18. 18.
    Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, et al. Specific oral tolerance induction in children with very severe cow’s milk-induced reactions. J Allergy Clin Immunol. 2008;121(2):343–7.CrossRefGoogle Scholar
  19. 19.
    Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D, La Rosa M, et al. Oral immunotherapy for cow’s milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol. 2010;105(5):376–81.CrossRefGoogle Scholar
  20. 20.
    Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119(1):199–205.CrossRefGoogle Scholar
  21. 21.
    Vickery BP, Pons L, Kulis M, Steele P, Jones SM, Burks AW. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010;105(6):444–50.CrossRefGoogle Scholar
  22. 22.
    Jones SM, Burks AW, Keet C, Vickery BP, Scurlock AM, Wood RA, et al. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol. 2016;137(4):1117–1127.e10.CrossRefGoogle Scholar
  23. 23.
    Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014;383(9925):1297–304.CrossRefGoogle Scholar
  24. 24.
    Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LC, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126(1):83–91.e1.CrossRefGoogle Scholar
  25. 25.
    Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654–60.CrossRefGoogle Scholar
  26. 26.
    • Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173–181.e8 Study showing the safety and efficacy of peanut OIT in young children. CrossRefGoogle Scholar
  27. 27.
    •• Bird JA, Spergel JM, Jones SM, Rachid R, Assa’ad AH, Wang J, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476–485.e3 Phase 2 results from AR101 product that will be submitted to the FDA for new drug licensing. CrossRefGoogle Scholar
  28. 28.
    Wood RA. Food allergen immunotherapy: current status and prospects for the future. J Allergy Clin Immunol. 2016;137(4):973–82.CrossRefGoogle Scholar
  29. 29.
    •• Scurlock AM, Jones SM. Advances in the approach to the patient with food allergy. J Allergy Clin Immunol. 2018;141(6):2002–14 Excellent overview of diagnosis, management, and treatment approaches to food allergy. CrossRefGoogle Scholar
  30. 30.
    Sanchez-Garcia S, Rodriguez Del Rio P, Escudero C, Martinez-Gomez MJ, Ibanez MD. Possible eosinophilic esophagitis induced by milk oral immunotherapy. J Allergy Clin Immunol. 2012;129(4):1155–7.CrossRefGoogle Scholar
  31. 31.
    Ridolo E, De Angelis GL, Dall’aglio P. Eosinophilic esophagitis after specific oral tolerance induction for egg protein. Ann Allergy Asthma Immunol. 2011;106(1):73–4.CrossRefGoogle Scholar
  32. 32.
    Begin P, Winterroth LC, Dominguez T, Wilson SP, Bacal L, Mehrotra A, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014;10(1):1-1492-10-1.Google Scholar
  33. 33.
    Dantzer JA, Wood RA. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy. 2018 Mar;48(3):232–40.CrossRefGoogle Scholar
  34. 34.
    Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol. 2015;135(3):737–44.e8.CrossRefGoogle Scholar
  35. 35.
    Goldberg MR, Nachshon L, Appel MY, Elizur A, Levy MB, Eisenberg E, et al. Efficacy of baked milk oral immunotherapy in bakedmilk-reactive allergic patients. J Allergy Clin Immunol. 2015; 136(6):1601-1606.Google Scholar
  36. 36.
    Srivastava KD, Siefert A, Fahmy TM, Caplan MJ, Li XM, Sampson HA. Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy. J Allergy Clin Immunol. 2016;138(2):536–543.e4.CrossRefGoogle Scholar
  37. 37.
    Srivastava KD, Bardina L, Sampson HA, Li XM. Efficacy and immunological actions of FAHF-2 in a murine model of multiple food allergies. Ann Allergy Asthma Immunol. 2012;108(5):351–358.e1.CrossRefGoogle Scholar
  38. 38.
    Srivastava KD, Kattan JD, Zou ZM, Li JH, Zhang L, Wallenstein S, et al. The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol. 2005;115(1):171–8.CrossRefGoogle Scholar
  39. 39.
    Srivastava KD, Song Y, Yang N, Liu C, Goldberg IE, Nowak-Wegrzyn A, et al. B-FAHF-2 plus oral immunotherapy (OIT) is safer and more effective than OIT alone in a murine model of concurrent peanut/tree nut allergy. Clin Exp Allergy. 2017;47(8):1038–49.CrossRefGoogle Scholar
  40. 40.
    Wang J, Jones SM, Pongracic JA, Song Y, Yang N, Sicherer SH, et al. Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (food allergy herbal formula-2) for food allergy. J Allergy Clin Immunol. 2015;136(4):962–970.e1.CrossRefGoogle Scholar
  41. 41.
    Dunn Galvin A, McMahon S, Ponsonby AL, Hsiao KC, Tang MLK. PPOIT study team. The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life. Allergy. 2018;73(3):560–8.CrossRefGoogle Scholar
  42. 42.
    Xolair(R) [package insert]. Genentech, Inc., South San Francisco, CA, 2007. 2017; Available at: Accessed September 12, 2017.
  43. 43.
    Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3(2):85–94.CrossRefGoogle Scholar
  44. 44.
    • Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–10.e1–11 Study showing that omalizumab plus OIT improved safety, but not efficacy. CrossRefGoogle Scholar
  45. 45.
    MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873–881.e8.CrossRefGoogle Scholar
  46. 46.
    Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011 Jun;127(6):1622–4.CrossRefGoogle Scholar
  47. 47.
    Lin C, Lee IT, Sampath V, Dinakar C,DeKruyff RH, Schneider LC, et al. Combining anti-IgEwith oral immunotherapy. Pediatr Allergy Immunol. 2017; 28(7): 619-627.Google Scholar
  48. 48.
    •• Jones SM, Sicherer SH, Burks AW, Leung DY, Lindblad RW, Dawson P, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139(4):1242–1252.e9 Phase II results on the safety and efficacy of Viaskin peanut patch therapy, which was submitted to the FDA for licensing in October 2018. CrossRefGoogle Scholar
  49. 49.
    Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H, Benhamou PH. Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010 May;125(5):1165–7.CrossRefGoogle Scholar
  50. 50.
    Jones SM, Agbotounou WK, Fleischer DM, Burks AW, Pesek RD, Harris MW, et al. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: a phase 1 study using the Viaskin patch. J Allergy Clin Immunol. 2016;137(4):1258–1261.e10.CrossRefGoogle Scholar
  51. 51.
    Feuille E, Nowak-Wegrzyn A. Allergen-specific immunotherapies for food allergy. Allergy Asthma Immunol Res. 2018;10(3):189–206.CrossRefGoogle Scholar
  52. 52.
    Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318(18):1798–809.CrossRefGoogle Scholar
  53. 53.
    Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–82.e1–6.CrossRefGoogle Scholar
  54. 54.
    Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129(2):448–55 455.e1–5.CrossRefGoogle Scholar
  55. 55.
    Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127(3):640–6.e1.CrossRefGoogle Scholar
  56. 56.
    Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119–27.e1–7.CrossRefGoogle Scholar
  57. 57.
    Burks AW, Wood RA, Jones SM, Sicherer SH, Fleischer DM, Scurlock AM, et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol. 2015;135(5):1240–8.e1–3.CrossRefGoogle Scholar
  58. 58.
    de Boissieu D, Dupont C. Sublingual immunotherapy for cow’s milk protein allergy: a preliminary report. Allergy. 2006;61(10):1238–9.CrossRefGoogle Scholar
  59. 59.
    Enrique E, Pineda F, Malek T, Bartra J, Basagana M, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116(5):1073–9.CrossRefGoogle Scholar
  60. 60.
    Kinaciyan T, Nagl B, Faustmann S, Frommlet F, Kopp S, Wolkersdorfer M, et al. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy. J Allergy Clin Immunol. 2018;141(3):1002–8.CrossRefGoogle Scholar
  61. 61.
    Manka LA, Wechsler ME. New biologics for allergic diseases. Expert Rev Clin Immunol. 2018;14(4):285–96.CrossRefGoogle Scholar
  62. 62.
    Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348(11):986–93.CrossRefGoogle Scholar
  63. 63.
    Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127(5):1309–10.e1.CrossRefGoogle Scholar
  64. 64.
    Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130(5):1123–1129.e2.CrossRefGoogle Scholar
  65. 65.
    Muto T, Fukuoka A, Kabashima K, Ziegler SF, Nakanishi K, Matsushita K, et al. The role of basophils and proallergic cytokines, TSLP and IL-33, in cutaneously sensitized food allergy. Int Immunol. 2014;26(10):539–49.CrossRefGoogle Scholar
  66. 66.
    Marco Londei M, Brian Kenney B, Gerrit Los P, Margaret MP. A phase 1 study of ANB020, an anti-IL-33 monoclonal antibody, in healthy volunteers. J Am Acad Dermatol. 2017; 2018/11;76(6):AB20.Google Scholar
  67. 67.
    Wood RA, Sicherer SH, Burks AW, Grishin A, Henning AK, Lindblad R, et al. A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy. 2013;68(6):803–8.CrossRefGoogle Scholar
  68. 68.
    Bindslev-Jensen C, de Kam P, van Twuijver E, Boot DB, El Galta R, Mose AP, et al. SCIT-treatment with a chemically modified, aluminum hydroxide adsorbed peanut extract (HAL-MPE1) was generally safe and well tolerated and showed immunological changes in peanut allergic patients. J Allergy Clin Immunol. 2017; 2018/10;139(2):AB191.CrossRefGoogle Scholar
  69. 69.
    Zuidmeer-Jongejan L, Huber H, Swoboda I, Rigby N, Versteeg SA, Jensen BM, et al. Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy. Int Arch Allergy Immunol. 2015;166(1):41–51.CrossRefGoogle Scholar
  70. 70.
    Prickett SR, Voskamp AL, Phan T, Dacumos-Hill A, Mannering SI, Rolland JM, et al. Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic. Clin Exp Allergy. 2013;43(6):684–97.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Su Y, Connolly M, Marketon A, Heiland T. CryJ-LAMP DNA vaccines for Japanese Red Cedar allergy induce robust Th1-type immune responses in murine model. J Immunol Res. 2016;2016:4857869.CrossRefGoogle Scholar
  72. 72.
    Su Y, Romeu-Bonilla E, Anagnostou A, Fitz-Patrick D, Hearl W, Heiland T. Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: a phase I study. Hum Vaccin Immunother. 2017;13(12):2804–13.CrossRefGoogle Scholar
  73. 73.
    Chin SJ, Vickery BP, Kulis MD, Kim EH, Varshney P, Steele P, et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J Allergy Clin Immunol. 2013;132(2):476–8.e2.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Pediatric Allergy and Immunology, Department of PediatricsJohn Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations